7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $85M | -$140M | 0.0% | -187.2% | -$110M | — | $60M |
| 2024 | $37000 | -$161M | 0.0% | -507678.4% | -$138M | — | $149M |
| 2023 | $21M | -$101M | 0.0% | -544.6% | -$79M | — | $249M |
| 2022 | $3M | -$107M | 0.0% | -3516.5% | -$98M | — | $52M |
| 2021 | $18M | -$71M | 0.0% | -395.5% | -$78M | — | $153M |
| 2020 | $13M | -$57M | 0.0% | -424.0% | -$52M | — | $277M |
| 2019 | $7M | -$49M | 0.0% | -729.4% | -$40M | — | $50M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $3M | -$69M | 0.0% | -2416.1% | — | — | $72M |
| Dec '25 | $85M | $19M | 0.0% | 17.3% | $29M | — | $60M |
| Sep '25 | $90000 | -$57M | 0.0% | -67983.3% | -$46M | — | $49M |
| Jun '25 | $15000 | -$55M | 0.0% | -396373.3% | -$43M | — | $77M |
| Mar '25 | $14000 | -$48M | 0.0% | -383007.1% | -$48M | — | $134M |
| Dec '24 | $1000 | -$50M | 0.0% | -5611700.0% | -$47M | — | $149M |
| Sep '24 | $3000 | -$44M | 0.0% | -1704400.0% | -$31M | — | $188M |
| Jun '24 | $5000 | -$35M | 0.0% | -849120.0% | -$31M | — | $189M |
| Mar '24 | $28000 | -$32M | 0.0% | -136200.0% | -$30M | — | $276M |
| Dec '23 | -$19000 | -$32M | 0.0% | 192905.3% | -$25M | — | $249M |
| Sep '23 | $20M | -$10M | 0.0% | -69.2% | -$2M | — | $276M |
| Jun '23 | $239000 | -$30M | 0.0% | -13446.0% | -$23M | — | $236M |
| Mar '23 | $298000 | -$29M | 0.0% | -10102.7% | -$29M | — | $79M |
| Dec '22 | $1M | -$27M | 0.0% | -2303.1% | -$23M | — | $52M |
| Sep '22 | $500000 | -$26M | 0.0% | -5299.0% | -$23M | — | $108M |
| Jun '22 | $162000 | -$28M | 0.0% | -17546.9% | -$22M | — | $113M |
| Mar '22 | $1M | -$26M | 0.0% | -2165.1% | -$30M | — | $76M |
| Dec '21 | $92000 | -$25M | 0.0% | -26917.4% | -$27M | — | $153M |
| Sep '21 | $1M | -$22M | 0.0% | -1658.9% | -$18M | — | $91M |
| Jun '21 | $15M | -$8M | 0.0% | -52.1% | -$17M | — | $244M |
How the market has priced FDMT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, 4d Molecular Therapeutics, Inc.'s revenue has grown 44.8% per year. These are computed facts, not advice.
As of FY2025, 4d Molecular Therapeutics, Inc. reported — of total debt against $60M of cash.
In FY2025, gross margin was —, operating margin -187.2%, and net margin -164.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.